LSD-assisted therapy trials at 100-200 mcg, is the clinical framework actually scalable?

Posted by curious_scientist in Research & News - 5 points, 4 comments.

Been following the LSD therapy research stuff for a while now. The clinical trials using 100-200 mcg in supervised sessions interest me more than the microdosing hype ever did. The mechanism is straightforward, 5-HT2A activation changing brain network communication, and the long duration actually makes sense for therapeutic work. You get hours to work through something instead of a 20-minute window.

What I keep wondering about is scalability. These trials are one to a few supervised sessions with support staff. That is expensive. Really expensive. How does this ever become accessible to regular people if it requires that kind of infrastructure?

The raised heart rate and blood pressure side effects also make me think this is not gonna be a free-for-all. Anyone with cardiovascular stuff is probably excluded or should be talking to their doctor first.

I tried low dose methylene blue for focus recently and even that felt like something to be careful with. LSD is a whole different animal. The distressing experience risk without proper support is real imo.

Anyone here actually following the MAPS-adjacent LSD trials closely? Curious whether the anxiety-in-serious-illness results are holding up as they expand to broader depression studies.

Comments

• student748: For what it is worth the scalability question is the one i keep coming back to too. Even if the trial data is solid, the infrastructure cost per patient is massive. Trained therapists, session rooms, follow-up integration visits, it adds up fast. No idea how that gets cheaper without compromising the safety side. The cardiovascular screening point is spot on. I have seen enough stress responses in healthy people to know that 200 mcg is not trivial physiologically. Anyone with borderline BP or a
• curious_scientist: I hear you on the cost side – those therapist hours and session rooms really add up fast, and scaling that without cutting safety feels like a tough nut. I tried low dose methylene blue just to see if it took the edge off the heart‑rate bump during a session; I felt a bit steadier but it’s hard to say if it was real or placebo. Curious if others have stacked anything to smooth the physiologic load.
• labrat_vik: The cardio screening thing gets undersold in these discussions, 5-HT2A agonism isn't just a brain thing, it hits vascular tone too and 200 mcg can absolutely spike BP and heart rate in someone who's already borderline. As for scalability, I think the realistic path is some hybrid model where the integration work gets delegated to lower-cost staff, but the dosing day stays tightly supervised. Whether insurance ever touches it though, that's a whole different fight.
• curious_scientist: The vascular tone point is exactly what I was getting at, people think 5-HT2A is just about brain networks but it is systemic. The hybrid model idea makes sense to me, delegate the integration prep and follow-up to therapists or social workers, keep the dosing day medical. But yeah, insurance covering this feels like a long shot. Do you think the supervision requirement on dosing day ever gets relaxed, or is that permanently locked in?

Community discussion - research and educational context only. Not medical advice.